Instruction for use: Tanyz-K

Trade name of the drug – Tanyz®-K

Active substance: Tamsulosinum

Dosage Form: Modified release capsule

Composition (per tablet):

pellet core

active substance: Tamsulosin hydrochloride - 0.4 mg

Other ingredients: MCC - 276.9 mg; methacrylic and ethacrylic acid copolymer, 1: 1 (30% dispersion emulsifiers - polysorbate 80, sodium lauryl sulfate) - 16.5 mg; triethyl citrate - 1.65 mg; Talc - 16.5 mg; Purified water (partially removed during the drying process of wood pellets to the mass loss (LOD) = 2-4%) - 12,48 mg

mass pellet core - 324.43 mg

shell pellets: methacrylic and ethacrylic acid copolymer, 1: 1 (30% dispersion emulsifiers - polysorbate 80, sodium lauryl sulfate) - 21.63 mg; talc - 8.65 mg; triethylcitrate - 2.16 mg

weight shell pellets - 32.44 mg

the mass of the capsule contents - 356.87 mg

capsule composition

Composition of the capsule shell: dye iron oxide red (E172) - 0.0239 mg; titanium dioxide (E171) - 0.53 mg; dye iron oxide yellow (E172) - 0,258 mg; gelatin - 38.938 mg

Composition cap capsules: indigo carmine FD & C Blue 2 (E132) - 0.00152 mg; dye iron oxide black (E172) - 0.0107 mg; titanium dioxide (E171) - 0.356 mg; Yellow dye iron dioxide (E172) - 0,114 mg; gelatin - 23.268 mg

Ink Composition: shellac glaze - 59.42% (20% esterified in ethanol); dye iron oxide black (E172) - 24.65%; butanol - 9.75%; Purified water - 3,249%; Propylene Glycol - 1.3%; Anhydrous Ethanol - 1.08%; Isopropyl alcohol - 0.55%; ammonium hydroxide - 28%

Pharmacotherapeutic group:

Alpha1-blocker [alpha-blockers]

Alpha1-blocker [Drugs affecting the metabolism of the prostate gland and correctors urodynamics]

ATX C04AE02 Nicergoline

The nosological classification (ICD-10)

N40 Hyperplasia of prostate gland: Prostate adenoma; BPH; Prostatauxe; prostate Hypertrophy; Dysuric disorders caused by benign prostatic hyperplasia; Dizuricheskie disorder with benign prostatic hyperplasia; Dysuria with prostate cancer; Benign prostatic giperpalaziya; Benign prostatic hyperplasia; Benign prostatic hyperplasia stages 1 and 2; Benign prostatic hyperplasia I degree; Benign prostatic hyperplasia II degree; Benign prostatic hypertrophy; The disease of the prostate gland; Acute urinary retention related to benign prostatic hyperplasia; Benign prostatic hyperplasia stages 1 and 2 in combination with prostatitis; paradoxical ischuria

Pharmacological Properties of Tanyz®-K

Pharmachologic effect - Mode of action - alpha adrenoliticheskoe, antidizuricescoe.

Tanyz®-K Dosage and Administration

Inside, without breaking, not liquid, after the first meal, drinking plenty of water in a sitting or standing position. 0.4 mg (1 capsule.) Per day.

Manufacturer

JSC "Krka, dd, Novo mesto." Smarjeske cesta 6, 8501 Novo mesto, Slovenia.

Produced by: Synthon BV. Netherlands.

Representative office of JSC «Krka, dd, Novo mesto" in the Russian Federation / organization receiving consumer complaints: 125212, Moscow, Golovinskoye Highway 5, Bldg. 1 fl. 22.

Tel .: (495) 981-10-88; fax (495) 981-10-90.

Release Form

Capsules depot, 0.4 mg. On 10 caps. in a blister; 1, 2, 3, 6, 9 and 20 are packaged in blister cardboard pack.

Storage conditions of Tanyz®-K

The temperature is not above 25 ° C. In its original packaging.

Keep out of the reach of children.

Shelf life

3 years.

Do not use beyond the expiration date printed on the package.

Conditions of supply of pharmacies

On prescription.